Cargando…
Peptidomimetics designed to bind to RAS effector domain are promising cancer therapeutic compounds
Oncogenic RAS proteins are important for driving tumour formation, and for maintenance of the transformed phenotype, and thus their relevance as a cancer therapeutic target is undeniable. We focused here on obtaining peptidomimetics, which have good pharmacological properties, to block Ras–effector...
| Autores principales: | , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Nature Publishing Group UK
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9499927/ https://www.ncbi.nlm.nih.gov/pubmed/36138080 http://dx.doi.org/10.1038/s41598-022-19703-6 |